Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilastatin/imipenem/relebactam - Merck Sharp and Dohme

Drug Profile

Cilastatin/imipenem/relebactam - Merck Sharp and Dohme

Alternative Names: Cilastatin/relebactam/imipenem; IMI/REL; Imipenem/cilastatin/relebactam; Imipenem/relebactam/cilastatin; MK-7655A; RECARBRIO; Relebactam + imepenem/cilastatin; Relebactam/cilastatin/imipenem; Relebactam/imipenem/cilastatin

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Anti-infectives; Antibacterials; Azabicyclo compounds; Carbapenems; Cyclopropanes; Piperidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Exopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
  • Registered Bacteraemia; Bacterial infections
  • Phase II/III Gram-negative infections
  • No development reported Sepsis

Most Recent Events

  • 07 May 2024 Merck completes the phase II/III trials in Gram-negative infections (In adolescents, In children, In infants, In neonates) in US, Colombia, Poland, France, South Africa, Russia, Bulgaria, Chile, Estonia, Greece, Hungary, Israel, Mexico, Norway, Philippines, Spain, Turkey and Ukraine (IV) (NCT03969901)
  • 11 Oct 2023 Efficacy and adverse events data from a phase III trial in Nosocomial pneumonia and Ventilator-associated-pneumonia presented at the IDWeek 2023 (IDW-2023)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Gram-negative-infections(In adolescents, In children, In infants, In neonates) in Bulgaria (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top